Literature DB >> 8589164

Methicillin-resistant Staphylococcus aureus as a community organism.

F Moreno1, C Crisp, J H Jorgensen, J E Patterson.   

Abstract

An increase in methicillin-resistant Staphylococcus aureus (MRSA) infections prompted a study of MRSA during a 21-month period in a 600-bed university hospital in southern Texas. MRSA cases were classified as community, nosocomial, or transfer cases. A case-control study of risk factors for community MRSA compared with community methicillin-susceptible S. aureus (MSSA) was performed. Pulsed field gel electrophoresis (PFGE) of whole cell DNA typing was used as a marker of strain identity for 31 consecutive isolates collected during the last 8 months of the study. During the 21 months there were 170 patients with MRSA infection or colonization, an incidence of 0.2 per 1,000 patient-days. Ninety-nine (58%) of 170 isolates were from community cases; the community to nosocomial case ratio was 2:1. No significant risk factors differentiated patients with community MRSA compared with community MSSA. Most community MRSA isolates studied (15 [68%] of 22) had distinct PFGE patterns, as did many nosocomial MRSA isolates (4 [44%] of 9). MRSA isolates were commonly present on admission to the hospital, and multiple MRSA strains were demonstrated among both community and hospital isolates.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8589164     DOI: 10.1093/clinids/21.5.1308

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  43 in total

1.  Community acquisition of gentamicin-sensitive methicillin-resistant Staphylococcus aureus in southeast Queensland, Australia.

Authors:  G R Nimmo; J Schooneveldt; G O'Kane; B McCall; A Vickery
Journal:  J Clin Microbiol       Date:  2000-11       Impact factor: 5.948

2.  Community-acquired Methicillin-resistant Staphylococcus aureus: Epidemiology and Potential Virulence Factors.

Authors:  Jose M. Eguia; Henry F. Chambers
Journal:  Curr Infect Dis Rep       Date:  2003-12       Impact factor: 3.725

Review 3.  Antimicrobial resistance: the example of Staphylococcus aureus.

Authors:  Franklin D Lowy
Journal:  J Clin Invest       Date:  2003-05       Impact factor: 14.808

Review 4.  Methicillin resistant Staphylococcus aureus (MRSA) in the intensive care unit.

Authors:  A S Haddadin; S A Fappiano; P A Lipsett
Journal:  Postgrad Med J       Date:  2002-07       Impact factor: 2.401

5.  Community-associated methicillin-resistant Staphylococcus aureus skin infections in a religious community.

Authors:  F Coronado; J A Nicholas; B J Wallace; D J Kohlerschmidt; K Musser; D J Schoonmaker-Bopp; S M Zimmerman; A R Boller; D B Jernigan; M A Kacica
Journal:  Epidemiol Infect       Date:  2006-07-26       Impact factor: 2.451

6.  Antimicrobial susceptibility patterns and staphylococcal cassette chromosome mec types of, as well as Panton-Valentine leukocidin occurrence among, methicillin-resistant Staphylococcus aureus isolates from children and adults in middle Tennessee.

Authors:  Abdullah Kilic; Haijing Li; Charles W Stratton; Yi-Wei Tang
Journal:  J Clin Microbiol       Date:  2006-10-25       Impact factor: 5.948

7.  Community-based cluster of methicillin-resistant Staphylococcus aureus in Manitoba.

Authors:  C A Kurbis; J L Wylie
Journal:  Can J Infect Dis       Date:  2001-05

8.  Is methicillin-resistant Staphylococcus aureus an emerging community pathogen? A review of the literature.

Authors:  M A Gardam
Journal:  Can J Infect Dis       Date:  2000-07

9.  Epidemiology and clinical features of methicillin-resistant Staphylococcus aureus in the University Hospital, Jeddah, Saudi Arabia.

Authors:  Tariq A Madani
Journal:  Can J Infect Dis       Date:  2002-07

10.  Outbreaks of infection caused by community-acquired methicillin-resistant Staphylococcus aureus in a Canadian correctional facility.

Authors:  Cheryl L Main; Padman Jayaratne; Allan Haley; Candy Rutherford; Fiona Smaill; David N Fisman
Journal:  Can J Infect Dis Med Microbiol       Date:  2005-11       Impact factor: 2.471

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.